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B d DS86 J Lif St d (LSS) d t f 1993– ase  on  ,  apanese  e‐span  u y    a a  rom  , 
and mortality risk transfer model
• Recent analysis of Low LET Risk Coefficients were made by 
UNSCEAR BEIR VII and Preston et al (2007),    ,        . 
– DS02 Dose estimates and longer follow‐up times of LSS
• NASA comparison of recent approaches for Space Station 
and Exploration planning requirements:     
– Incidence based Risk Transfer is preferred model (BEIR VII)
– UNSCEAR tissue specific incidence models for risk coefficients 
Ri k f N k h A id d– s s  or  ever‐smo ers suc  as  stronauts cons ere
• Reduces lung, esophagus, stomach and bladder cancer risks 
compared to Ave. U.S. Model


























Cell Lung Cancer a critical question
Thun et al., PLoS Med (2008)










Esophagus 6 76 4 46 1 0 27. . .
Stomach 1.96 1.47 1 0.71
Bladder 3.27 2.09 1 0.50
Oral Cavity 10.89 3.4 1 0.23




Esophagus 7.75 2.79 1 0.35
Stomach 1.36 1.32 1 0.85
Bladder 2.22 1.89 1 0.65
Oral Cavity 5.08 2.29 1 0.46








































Fatal lung cancer risks per Sv (DDREF=2)
Transfer model impact much larger change than >100 cm of GCR
National Aeronautics and Space Administration 
           
shielding– the 100 Billion Dollar question?
% REID, Females % REID, Males
Age at Exposure 35, y 45, y 55, y 35, y 45, y 55, y
Model Type Model rates Average U.S. Population, 2005
Additive BEIR VII 1.20 1.20 1.18 0.65 0.66 0.66
UNSCEAR 1.28 1.27 1.22 0.71 0.71 0.69
RERF 1.33 1.34 1.32 0.72 0.73 0.73
Multiplicative BEIR VII 2.88 2.74 2.38 0.95 0.92 0.83
UNSCEAR 3.56 3.50 3.23 1.17 1.17 1.11
RERF 3.71 4.16 4.21 1.13 1.30 1.37
Mixture BEIR VII 2.04 1.97 2.78 0.80 0.79 0.74
UNSCEAR 2 43 2 39 2 23 0 94 0 94 0 89. . . . . .
RERF 2.53 2.77 2.78 0.92 1.02 1.05
Never-smokers
Multiplicative BEIR VII 0.44 0.41 0.37 0.15 0.15 0.14
UNSCEAR 0.57 0.57 0.54 0.15 0.15 0.14
RERF 0 55 0 61 0 66 0 14 0 15 0 16. . . . . .
Mixture BEIR VII 0.85 0.84 0.81 0.40 0.40 0.38
UNSCEAR 0.96 0.95 0.91 0.46 0.45 0.42
RERF 0.98 1.01 1.02 0.46 0.47 0.45
Generalized RERF, Generalized 0.39 0.47 0.53 0.16 0.17 0.20






i f d b i i di bi l
Thacker et al. 1979










• ICRP assume ion with higher Z





           
has higher effectiveness than 
lower Z at fixed LET; not 



















guide choice on functional forms       









ll d f d b b l d b f ( ) f• We   e ine  Pro a i ity  istri ution  unctions  PDF  to account  or 
variation of possible parameter values (0, m, and )
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“Standard Model” due to low LET uncertainties alone             
Analysis %Risk for 0.1 Sv Comment
NCRP Report 126 0.37 [0.115, 0.808] Gender avg. with 90% CI
BEIR VII Males 0.48 [0.24, 0.98] 95% CI
BEIR VII Female 0.74 [0.37, 1.5] 95% CI
UNSCEAR Solid Cancer 0 502 [0 28 0 735] Gender avg with 90% CI. . , .   .      ,  
DDREF uncert. not 
considered
UNSCEAR Leukemia 0.061 [0.014, 0.118] Gender avg. with 90% CI
14
NASA 2010 0.38 [0.139, 0.76] 40‐y Female Never‐smoker
with 95% CI
“Safe” days in Space: Uncertainties estimated using 
subjective PDFs propagated using Monte‐Carlo techniques
National Aeronautics and Space Administration 
         
%REID predictions and 95% CI for never‐smokers and average U.S. population for 1‐year 
in deep space at solar minimum with 20 g/cm2 aluminum shielding:
%REID for Males  and 95% CI %REID for Females and 95% CI
aE, y Avg. U.S. Never-Smokers Decrease
(%)
Avg. U.S. Never-Smokers Decrease
(%)
30 2.26 [0.76, 8.11] 1.79 [0.60, 6.42] 21 3.58 [1.15, 12.9] 2.52 [0.81, 9.06] 30
40 2.10 [0.71, 7.33] 1.63 [0.55, 5.69] 22 3.23 [1.03, 11.5] 2.18 [0.70, 7.66] 33
50 1.93 [0.65, 6.75] 1.46 [0.49, 5.11] 24 2.89 [0.88, 10.2] 1.89 [0.60, 6.70] 34
Maximum Days in Deep Space with 95% Confidence to be below Limits (alternative 
aE, y NASA 2005 NASA 2010





35 158 140 (186) 180 (239)
45 207 150 (200) 198 (263)
55 302 169 (218) 229 (297)
Females
35 129 88 (120) 130 (172)
45 173 97 (129) 150 (196)




























l d t t t t d ff t Dose, Gy










Rat mammary (1.0 GeV/u)
Mice Liver (1.0 GeV/u)
Mice H. Gland (0.6 GeV/u)
ow  ose  o represen  non‐ arge e  e ec s. 
– NTE model provides best fit to data
• Heavy ion experiments related to cancer 





NTE at  0.05 Gy
NTE at 0.2 Gy
TE RBEmax
 
































































































bi l i l t t M d l f k
National Aeronautics and Space Administration 
o og ca  sys ems sugges s a  o u ar  ramewor














• Pathway modeling made on at least 3 levels             
– Molecular binding and interaction
– Deterministic O.D.E.










































h t M d l t bi l t d lapproac   o  o u ar sys ems  o ogy  o  eve op 
disease models is long‐range approach for NASA 
program
